Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma

Stopped early · Phase 2

Conditions studied: Metastatic Breast Cancer, Thyroid Dysfunction

In brief

Up to one third of breast cancer patients have hypothyroidism or hyperthyroidism. L-thyroxine (T4), or Synthroid, is the most commonly prescribed agent for the management of hypothyroidism in the US. However, there are data suggesting that triiodothyronine (T3) may have benefits in preventing disease progression over l-thyroxine (T4).

Key facts

Study ID

NCT03787303

Run by

Aultman Health Foundation

People needed

7

Starts

2019-03-01

Expected to finish

2022-03-09

Last updated by the study team

2022-05-13

Who can join

Age: 18 and older, up to 105. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age greater than or equal to 18
• Male or female with diagnosis of metastatic breast carcinoma and documented history of hypothyroidism .
• TSH level within normal range at baseline
• Life expectancy estimated > 3 months
• Ability and willingness to provide informed consent

You may not qualify if…

• Life expectancy estimated to be less than 3 months
• Is currently pregnant or intends to become pregnant during the duration of the study
• Active angina, New York Heart Association (NYHA) advanced [Class III/IV] congestive heart failure, or uncontrolled cardiac arrhythmia within 6 months of enrollment
• History of thyrotoxicosis
• History of adrenal insufficiency
• Hypersensitivity to any active or extraneous constituents in Triiodothyronine (T3)/liothyronine sodium

Where it is running

• Aultman Medical Group Hematology and Oncology — Canton, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.